{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:18:19Z","timestamp":1789957099713,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20240101183JC"],"award-info":[{"award-number":["20240101183JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170154"],"award-info":[{"award-number":["82170154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.actbio.2025.05.067","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:50:32Z","timestamp":1748775032000},"page":"591-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CD4+ T cell membrane-based nanocomposites for enhanced dual epigenetic therapy in psoriasis"],"prefix":"10.1016","volume":"201","author":[{"given":"Lin","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiannan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-1200","authenticated-orcid":false,"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2025.05.067_bib0001","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"10281","key":"10.1016\/j.actbio.2025.05.067_bib0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.actbio.2025.05.067_bib0003","volume":"2","author":"Greb","year":"2016","journal-title":"Psoriasis Nat. Rev. Dis. Primers"},{"issue":"10275","key":"10.1016\/j.actbio.2025.05.067_bib0004","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0006","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191123","article-title":"Targeting interleukin-17 in chronic inflammatory disease: a clinical perspective","volume":"217","author":"Zwicky","year":"2020","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.actbio.2025.05.067_bib0007","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.actbio.2025.05.067_bib0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10273","key":"10.1016\/j.actbio.2025.05.067_bib0009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.actbio.2025.05.067_bib0010","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23\u2013specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"19","key":"10.1016\/j.actbio.2025.05.067_bib0011","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMa"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jaci.2020.05.009","article-title":"Mechanisms of skin autoimmunity: cellular and soluble immune components of the skin","volume":"146","author":"Gudjonsson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0014","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.actbio.2025.05.067_bib0015","first-page":"376","article-title":"Cancer epigenetics in clinical practice","volume":"73","author":"Davalos","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.actbio.2025.05.067_bib0016","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/leu.2016.349","article-title":"Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells","volume":"31","author":"Yan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2025.05.067_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109294","article-title":"Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis","volume":"250","author":"Liu","year":"2023","journal-title":"Clin. Immunol."},{"issue":"19","key":"10.1016\/j.actbio.2025.05.067_bib0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100939118","article-title":"Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis","volume":"118","author":"Huang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"34","key":"10.1016\/j.actbio.2025.05.067_bib0019","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1073\/pnas.1501956112","article-title":"CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses","volume":"112","author":"Hammitzsch","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nature Rev. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.actbio.2025.05.067_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202402445","article-title":"Revolutionizing neurocare: biomimetic nanodelivery via cell membranes","volume":"36","author":"Liao","year":"2024","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.actbio.2025.05.067_bib0022","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","article-title":"Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"13","key":"10.1016\/j.actbio.2025.05.067_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201901255","article-title":"Biomimetic nanotechnology toward personalized vaccines","volume":"32","author":"Zhou","year":"2020","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.actbio.2025.05.067_bib0024","article-title":"Biomimetic and bioinspired nano-platforms for cancer vaccine development","volume":"3","author":"C.Feng","year":"2023","journal-title":"Exploration. (Beijing)"},{"key":"10.1016\/j.actbio.2025.05.067_bib0025","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41565-024-01618-0","article-title":"Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles","volume":"19","author":"Li","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"24","key":"10.1016\/j.actbio.2025.05.067_bib0026","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/smll.201200962","article-title":"Pd nanosheet-covered hollow mesoporous silica nanoparticles as a platform for the chemo-photothermal treatment of cancer cells","volume":"8","author":"Fang","year":"2012","journal-title":"Small."},{"issue":"2","key":"10.1016\/j.actbio.2025.05.067_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202107195","article-title":"Hepcidin-based nanocomposites for enhanced cancer immunotherapy by modulating iron export-mediated N6-methyladenosine RNA transcript","volume":"32","author":"Zhang","year":"2022","journal-title":"Adv. Funct. Mater."},{"issue":"13","key":"10.1016\/j.actbio.2025.05.067_bib0028","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.nanolett.1c00818","article-title":"Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy","volume":"21","author":"Chen","year":"2021","journal-title":"Nano Lett."},{"issue":"16","key":"10.1016\/j.actbio.2025.05.067_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202210895","article-title":"A bimetallic metal\u2013Organic-framework-based biomimetic nanoplatform enhances anti-leukemia immunity via synchronizing DNA demethylation and RNA hypermethylation","volume":"35","author":"Song","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.05.067_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.141426","article-title":"Gold Nanorod\u2013mesoporous silica core shell nanocomposites for NIR-II photothermal ablation and dual PD-L1\/VEGF blockade therapy in hepatocellular carcinoma","volume":"459","author":"Dai","year":"2023","journal-title":"Chem. Eng. J."},{"issue":"11","key":"10.1016\/j.actbio.2025.05.067_bib0031","doi-asserted-by":"crossref","first-page":"17689","DOI":"10.1021\/acsnano.1c05547","article-title":"Gold nanorods exhibit intrinsic therapeutic activity via controlling N 6-methyladenosine-based epitranscriptomics in acute myeloid leukemia","volume":"15","author":"Du","year":"2021","journal-title":"ACS. Nano"},{"issue":"13","key":"10.1016\/j.actbio.2025.05.067_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202106558","article-title":"Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells","volume":"18","author":"Cao","year":"2022","journal-title":"Small."},{"issue":"12","key":"10.1016\/j.actbio.2025.05.067_bib0033","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1021\/nn4053233","article-title":"Acid and alkaline dual stimuli-responsive mechanized hollow mesoporous silica nanoparticles as smart nanocontainers for intelligent anticorrosion coatings","volume":"7","author":"Fu","year":"2013","journal-title":"ACS. Nano"},{"issue":"10","key":"10.1016\/j.actbio.2025.05.067_bib0034","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nature Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.actbio.2025.05.067_bib0035","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1021\/acsnano.4c15761","article-title":"UiO-66 MOFs-based \u201cEpi-Nano-sonosensitizer\u201d for ultrasound-driven cascade immunotherapy against B-cell lymphoma","volume":"19","author":"Wang","year":"2025","journal-title":"ACS. Nano"},{"issue":"12","key":"10.1016\/j.actbio.2025.05.067_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202417707","article-title":"Lysosomal membrane-biomimetic metal-organic framework potentiates autophagy\/epigenetic-mediated anti-tumor immunity","volume":"35","author":"Wang","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"50","key":"10.1016\/j.actbio.2025.05.067_bib0037","doi-asserted-by":"crossref","first-page":"15989","DOI":"10.1021\/acs.nanolett.4c04264","article-title":"Erythrocyte-based biomimetic MOFs as a triple epigenetic regulator for enhancing anti-leukemia immunity","volume":"24","author":"Ding","year":"2024","journal-title":"Nano Lett."},{"issue":"9","key":"10.1016\/j.actbio.2025.05.067_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-023-00930-5","article-title":"Why do IL-17-targeted therapies have limited efficacy?","volume":"23","author":"Flemming","year":"2023","journal-title":"Nature Rev. Immunol."},{"key":"10.1016\/j.actbio.2025.05.067_bib0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11538950-000000000-00000","article-title":"New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab","volume":"12","author":"Kurzeja","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.actbio.2025.05.067_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.151613","article-title":"Synergistic chemo-photodynamic therapy based on hollow mesoporous organosilica nanoparticles for reducing psoriasis-like inflammation","volume":"490","author":"Fan","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"8","key":"10.1016\/j.actbio.2025.05.067_bib0041","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1021\/nn301622h","article-title":"Skin penetration and cellular uptake of amorphous silica nanoparticles with variable size, surface functionalization, and colloidal stability","volume":"6","author":"Rancan","year":"2012","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2025.05.067_bib0042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2022.01.019","article-title":"Noninvasive transdermal delivery of mesoporous silica nanoparticles using deep eutectic solvent","volume":"343","author":"Zhao","year":"2022","journal-title":"J. Controll. Rel."},{"issue":"12","key":"10.1016\/j.actbio.2025.05.067_bib0043","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1021\/acsnano.4c13533","article-title":"Enhance efferocytosis and block the macrophages\u2013Platelets feedback loop for targeted treatment of psoriasis","volume":"19","author":"Liu","year":"2025","journal-title":"ACS. Nano"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0044","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41467-024-46130-0","article-title":"A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.actbio.2025.05.067_bib0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ni.3347","article-title":"Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid","volume":"17","author":"Jin","year":"2016","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0046","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-017-02794-5","article-title":"Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.067_bib0047","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:30:36Z","timestamp":1776843036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125004027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"alternative-id":["S1742706125004027"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.067","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD4+ T cell membrane-based nanocomposites for enhanced dual epigenetic therapy in psoriasis","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}